Company: CALX
Filing Date: 2025-03-27
Form Type: DEF 14A
Source: 0001406666-25-000011
Chunk: 96

Company: CALIX, INC
Filing Date: 2025-03-27
Form: DEF 14A
Chunk 96
---
-   
 Average     
 Exercise    
 Price of    
 Outstanding 
 Options     
 (b)         |       |     |    |     | Number of     
 Securities    
 Remaining     
 Available for 
 Future        
 Issuance      
 Under Equity  
 Compensation  
 Plans         
 (Excluding    
 Securities    
 Reflected in  
 Column (a))   |     |           |    |
|:-----------------------------------------------------------|:----|:--------------|:----|-----------:|:----|:------------|------:|:----|---:|:----|:--------------|:----|----------:|---:|
| Equity Compensation Plans Approved by Stockholders (1)     |     |               |     | 11,908,170 |     | $           | 34.37 |     |    |     |               |     | 9,298,880 | -4 |
| Equity Compensation Plans Not Approved by Stockholders (2) |     |               |     |    275,000 |     | $           |  5.05 |     |    |     |               |     |         — |    |
| Total                                                      |     |               |     | 12,183,170 |     | $           | 33.70 |     | -3 |     |               |     | 9,298,880 |    |

(1) Includes our 2010 Plan, 2019 Plan, ESPP and Nonqualified ESPP.

(2) Consists of a Nonstatutory Inducement Stock Option Grant, which constitutes an employment inducement award for Mr. Sindelar under NYSE Listed Company Manual Rule 303A.08 that was approved by the Talent and Compensation Committee on September 28, 2017. The NYSE approved the Supplemental Listing Application for the Inducement Award on October 30, 2017. The Nonstatutory Inducement Stock Option Grant was awarded on October 1, 2017 and provides Mr. Sindelar the right to purchase up to 300,000 shares of our common stock for an exercise price of $5.05 per share. The Nonstatutory Inducement Stock Option Grant has a term of 10 years and has vested. In the event of a termination of Mr. Sindelar’s employment, Mr. Sindelar would have three months, or 12 months in the case of death or disability, to exercise the option.

(3) The weighted-average remaining term for outstanding options is 7.